Non-rabbit mAbs often fail to detect difficult antigens (Ags)
such as small molecules, Ags with highly similar epitopes,
post-transcriptionally-modified Ags, and Ags with no
immunogenicity in mice. They also tend to require stringent
optimization protocols in order to work in certain applications,
possibly affecting the overall effectiveness of the experiment
and interpretation of the results.
In Vitro Diagnostics: A variety of
In Vitro diagnostic (IVD) assays, such as IHC, ELISA,
and radio immunoassays (RI) are based on the principles of
antigen-antibody binding. Given the critical role these assays
play in patient and animal care, it is extremely important that
IVD assays are carried out using the highest sensitivity and
affinity mAbs available.
In Vivo Imaging: Visualization of mAbs
can be accomplished through numerous means; however, the most
common method is through labelling of mAbs with radioactive or
fluorescent molecules to help track them in the body and aid in
quantifying the results.
In Vitro Diagnostics (IVD)
In Vivo Imaging
Anti-Idiotype Antibodies: Pharmacokinetic (PK)
assays are used to measure the absorption and excretion rates,
distribution, and half-life of candidate small molecules or mAb
therapeutics. Results from these assays help identify the
optimal dose and toxicity risks of a therapeutic molecule.
Therefore anti-idiotype antibodies need to be sensitive enough
to capture trace amounts of their antibody target in free,
bound, and total forms in biological fluid samples.
mAb therapeutics: The high specificity and
sensitivity of an antibody towards its target antigen reduces
both safety and toxicity concerns: highly specific antibodies
avoid off-target binding and hence, offer safety; highly
sensitive antibodies require low dosage administration and
hence, cause a minimum level of toxicity.
CAR-T mAb Based Therapeutic